1 – 10 of 33
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
(
- Contribution to journal › Article
- 2020
-
Mark
Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma
(
- Contribution to journal › Article
- 2019
-
Mark
Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival
(
- Contribution to journal › Article
- 2018
-
Mark
Low Frequency of Intratumor Heterogeneity in Bladder Cancer Tissue Microarrays
(
- Contribution to journal › Article
- 2017
-
Mark
HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
(
- Contribution to journal › Article
- 2015
-
Mark
Reply from Authors re: Bas W.G. van Rhijn, Mark A. Behrendt, Kees Hendricksen, Theo H. van der Kwast. Toward Optimal Prediction of Prognosis in T1 Urothelial Carcinoma of the Bladder. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.03.030.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.
(
- Contribution to journal › Article
- 2014
-
Mark
Infiltration of CD3(+) and CD68(+) cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors.
(
- Contribution to journal › Article
- 2013
-
Mark
Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
(
- Contribution to journal › Article
-
Mark
Toward a Molecular Pathologic Classification of Urothelial Carcinoma.
(
- Contribution to journal › Article